Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia

被引：0
|
作者：
Wang, Lijun [1 ]
Chen, Yu [2 ]
Wang, Qingyuan [1 ]
Xiang, Meng [1 ]
Zeng, Zhao [1 ]
Zhang, Zhibo [1 ]
Zhang, Fenghong [1 ]
Chen, Suning [1 ,3 ,4 ]
Xue, Mengxing [1 ,4 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Wannan Med Coll, Dept Hematol, Affiliated Hosp 2, Wuhu, Peoples R China
[3] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suning Chen & Mengxing Xue, Shizi St 188, Suzhou 215006, Peoples R China
来源：
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2024年 / 46卷 / 03期
基金：
中国国家自然科学基金;
关键词：
PAX5; TRANSFORMATION; GENE;
D O I：
10.1111/ijlh.14245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：571 / 574
页数：4
相关论文
共 50 条
  • [41] Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia
    de Campos, Mireille Guimaraes Vaz
    Tadeu Montesano, Fabio
    Madalena Rodrigues, Maria
    Ferrari Chauffaille, Maria de Lourdes Lopes
    CANCER GENETICS AND CYTOGENETICS, 2007, 178 (01) : 49 - 56
  • [42] PHASE-II CLINICAL-TRIAL WITH VINDESINE FOR REMISSION INDUCTION IN ACUTE-LEUKEMIA, BLASTIC CRISIS OF CHRONIC MYELOID-LEUKEMIA, LYMPHOSARCOMA, AND HODGKINS-DISEASE - ABSENCE OF CROSS-RESISTANCE WITH VINCRISTINE
    MATHE, G
    MISSET, JL
    DEVASSAL, F
    GOUVEIA, J
    HAYAT, M
    MACHOVER, D
    BELPOMME, D
    PICO, JL
    SCHWARZENBERG, L
    RIBAUD, P
    MUSSET, M
    JASMIN, C
    DELUCA, L
    CANCER TREATMENT REPORTS, 1978, 62 (05): : 805 - 809
  • [43] INFLUENCE OF CYP3A5 AND SLCO1 ON IMATINIB RESPONSE AMONG EGYPTIAN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA.
    Aref, S.
    El-Ghonemy, M.
    El Baiomy, M.
    HAEMATOLOGICA, 2015, 100 : 699 - 700
  • [44] Mobilization of peripheral blood progenitor cells in patients with chronic myeloid leukemia in chronic phase:: IC 5 days versus IC 3 days.
    Pönisch, W
    Freund, M
    Schultze, W
    Krahl, R
    Leiblein, S
    Ulrich, E
    Lange, T
    Kubel, M
    Lehmann, T
    Wilhelm, S
    Helbig, W
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 1999, 23 : S218 - S218
  • [45] A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia Diagnostic Challenges in Clinical Laboratory Practice
    Jinawath, Natini
    Norris-Kirby, Alexis
    Smith, B. Douglas
    Gocke, Christopher D.
    Batista, Denise A.
    Giriffin, Constance A.
    Murphy, Kathleen M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (04): : 359 - 363
  • [46] HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice
    Mauro, Michael
    Atallah, Ehab L.
    Thompson, James E.
    Gao, Yan
    Visotcky, Alexis
    Giever, Emily
    Baim, Arielle
    Akinola, Idayat
    Larson, Richard A.
    Jamy, Omer
    Cortes, Jorge
    Druker, Brian J.
    Shah, Neil P.
    Pinilla-Ibarz, Javier
    Yang, Jay
    Ritchie, Ellen K.
    Rein, Lindsay A. M.
    Tantravahi, Srinivas K.
    Badar, Talha
    Smith, B. Douglas
    Deininger, Michael W.
    Flynn, Kathryn E.
    BLOOD, 2023, 142
  • [47] Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML)
    Mauro, Michael J.
    Lang, Fabian
    Kim, Dong-Wook
    Cortes, Jorge E.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Minami, Hironobu
    Boquimpani, Carla
    Minami, Yosuke
    Breccia, Massimo
    Goh, Yeow-Tee
    Ottmann, Oliver
    Sondhi, Manu
    Hois, Stephan
    Bedoucha, Veronique
    Perraud, Kevin
    Rea, Delphine
    DeAngelo, Daniel J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S223 - S223
  • [48] Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
    Mauro, Michael J.
    Lang, Fabian
    Kim, Dong-Wook
    Cortes, Jorge E.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Minami, Hironobu
    Boquimpani, Carla
    Minami, Yosuke
    DeAngelo, Daniel J.
    Breccia, Massimo
    Talpaz, Moshe
    Goh, Yeow-Tee
    Ottmann, Oliver
    Sondhi, Manu
    Hois, Stephan
    Bedoucha, Veronique
    Schmitz, Shu-Fang Hsu
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3-and 6-month time points
    Lapusan, Simona
    Yong, Agnes
    Savani, Bipin N.
    Mohty, Mohamad
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (02) : 103 - 112
  • [50] Long-term 5-year results of the phase 3 DASISION trial (dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase [CML-CP])
    Stegelmann, F.
    Cortes, J.
    Saglio, G.
    Baccarani, M.
    Kantarjian, H.
    Mayeri, J.
    Bogue, C.
    Shah, N. P.
    Chuah, C.
    Casanova, L.
    Narayanan, G.
    Bradley-Garelik, B.
    Manos, G.
    Hochhaus, A.
    Oncology Research and Treatment, 2015, 38 : 23 - 24
12345